Compare Abbott Laboratories (ABT) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Abbott Laboratories trades at $95.5 (market cap $166.94B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $33.33. The key difference: Abbott Laboratories pays a 2.63% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and Abbott Laboratories is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ABT | TMF | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $136.62 | $44.14 |
52-Week Low | $82.57 | $31.85 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $34.62, down 0.46% on the day, with a bearish technical signal from moving averages. The fund provides 3x daily leveraged exposure to long-term U.S. Treasury bonds, making it highly sensitive to interest rate movements. Recent news highlights significant long-term value erosion, with a $10,000 investment five years ago now worth approximately $1,527, underscoring the risks of daily leverage reset in volatile markets.
The outlook for TMF hinges on the direction of long-term bond yields, with potential for sharp gains if rates fall but severe losses if they rise. It is suited only for short-term, high-risk traders due to leverage decay. Key risks include Federal Reserve policy shifts, inflation trends, and the structural drag of daily rebalancing, making it unsuitable for buy-and-hold investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
